Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 6/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618470 | 0.78 | S1PR1 (0.40) | ACHEOPRM1SIGMAR1 | |
| SCHEMBL23924608 | 0.77 | SIGMAR1 (0.52) | ALDH1A1DRD2SIGMAR1 | |
| SCHEMBL23924607 | 0.77 | SIGMAR1 (0.52) | ALDH1A1DRD2SIGMAR1 | |
| SCHEMBL23924502 | 0.77 | SIGMAR1 (0.52) | ALDH1A1DRD2SIGMAR1 | |
| SCHEMBL22010183 | 0.73 | HTR1A (0.48) | HTR1AADKSIGMAR1 | |
| SCHEMBL20521021 | 0.73 | HTR1A (0.48) | HTR1AADKSIGMAR1 | |
| SCHEMBL22605205 | 0.73 | HTR1A (0.48) | HTR1AADKSIGMAR1 | |
| SCHEMBL20521020 | 0.73 | HTR1A (0.48) | HTR1AADKSIGMAR1 | |
| SCHEMBL20521023 | 0.73 | HTR1A (0.48) | HTR1AADKSIGMAR1 | |
| SCHEMBL23850163 | 0.72 | ALDH1A1 (0.48) | ALDH1A1ACHEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323981-A1 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323981-A1 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | ARG1, PNISR, ARGLU1 | CCR5 269/4885ALDH1A1 2410/4885ACHE 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.